Drugs / Lingze
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07357324 | Dec 2024 → Dec 2026 expected | benign prostatic hyperplasia, nocturnal enuresis | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lingze | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07357324 ↗ |
| Known as | Lingze tablets | “Lingze tablets are a traditional Chinese patent medicine composed of herbal extracts including Rhizoma Alismatis, Poria, Radix Rehmanniae Preparata, Rhizoma Curculiginis, and...” NCT07357324 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “a traditional Chinese patent medicine” NCT07357324 ↗ |
| Route | Oral | “will be administered orally” NCT07357324 ↗ |